Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter‐laboratory study: Is it ready for primetime use?-Reference-Cited by-同舟云学术

Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter‐laboratory study: Is it ready for primetime use?

Published:2018-12-19 Issue:3 Volume:96 Page:201-208
ISSN:1552-4949
Container-title:Cytometry Part B: Clinical Cytometry
language:en
Short-container-title:Cytometry

Author:

Scott Stuart D.¹²,Fletcher Matthew¹,Whitehouse Helen¹,Whitby Liam¹^ORCID,Yuan Constance³^ORCID,Mazzucchelli Silvia⁴,Lin Pei⁵,de Tute Ruth⁶,Dorwal Pranav⁷,Wallace Paul K.⁸,Tembhare Prashant⁹^ORCID,Arroz Maria¹⁰,Snowden John A.²¹¹,Chantry Andrew D.²¹¹,Barnett David¹²¹¹

Affiliation:

1. UK NEQAS for Leucocyte ImmunophenotypingSheffield Teaching Hospitals Sheffield UK

2. Department of Oncology and Metabolism, Faculty of Medicine, Dentistry and HealthUniversity of Sheffield Sheffield UK

3. Clinical Flow Cytometry Laboratory, Laboratory of PathologyCCR, NCI, NIH Bethesda Maryland

4. Department of Haematology and Flow CytometrySynlab Suisse SA Bioggio Switzerland

5. Department of HematopathologyMD Anderson Cancer Center Houston Texas

6. HMDS, Department of HaematologySt. James's Institute of Oncology Leeds UK

7. Flow Cytometry LaboratoryWaikato Hospital Hamilton New Zealand

8. Department of Flow and Image CytometryRoswell Park Cancer Institute Buffalo New York

9. Hematopathology LaboratoryTata Memorial Center Mumbai Maharashtra India

10. Flow Cytometry Laboratory, Department of Clinical PathologyCHLO S. Francisco Xavier Hospital Lisbon Portugal

11. Department of HaematologySheffield Teaching Hospitals NHS Foundation Trust Sheffield UK

Publisher

Wiley

Subject

Cell Biology,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cyto.b.21754

Reference31 articles.

1. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance;Almeida J;Pathol Biol (Paris),1999

2. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome

3. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

4. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

5. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies;International Journal of Molecular Sciences;2024-07-15

2. Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant;HemaSphere;2024-04

3. Voyage of Measurable Residual Disease Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry;Indian Journal of Medical and Paediatric Oncology;2023-04-24

4. Consensus for Flow Cytometry Clinical Report on Multiple Myeloma: A Multicenter Harmonization Process Merging Laboratory Experience and Clinical Needs;Cancers;2023-03-30

5. Relevance of polyclonal plasma cells and post‐therapy immunomodulation in measurable residual disease assessment in multiple myeloma;Cytometry Part B: Clinical Cytometry;2022-04-07